Finch Therapeutics Group Inc. announced that it has appointed Ulrich Thienel, Ph.D., M.D., as Chief Medical Officer and Gregory Perry as Chief Financial Officer. Dr. Thienel will lead the clinical development of Finch's Full-Spectrum Microbiota™ and Rationally-Selected Microbiota™ platforms, while Mr. Perry will provide strategic financial and operational leadership at Finch. Dr. Thienel joins Finch with more than 20 years of experience successfully leading drug development programs for biotechnology and pharmaceutical companies, including RRD International, Takeda, Bristol-Myers Squibb, and Johnson & Johnson.

Dr. Thienel's development experience spans multiple therapeutic areas, including gastrointestinal, immunology, central nervous system, hematology, respiratory, and rare diseases. Mr. Perry brings more than 20 years of corporate finance experience in the biopharmaceutical industry, including leading the acquisition of three companies and raising $1 billion of capital in ten transactions, including an IPO. Prior to joining Finch, Mr. Perry held various senior financial leadership roles at several biotech companies including Novelion Therapeutics, Eleven Biotherapeutics, ImmunoGen, Domantis, and Transkaryotic Therapies.

Mr. Perry currently serves on the Board of Directors of Merus Therapeutics and Kala Pharmaceuticals.